<DOC>
	<DOCNO>NCT01315249</DOCNO>
	<brief_summary>The purpose study compare efficacy safety/tolerability indacaterol glycopyrronium ( QVA149 ) ( fixed-dose combination ) fluticasone/salmeterol 26-week period patient moderate severe COPD .</brief_summary>
	<brief_title>QVA149 Versus Fluticasone/Salmeterol Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Smoking history least 10 pack year Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease [ GOLD ] Guidelines , 2009 ) Postbronchodilator Forced Expiratory Volume 1 second ( FEV1 ) &gt; 40 % &lt; 80 % predict normal value postbronchodilator FEV1/Forced Vital Capacity ( FVC ) &lt; 70 % Patients COPD exacerbation require treatment antibiotic , systemic steroid ( oral intravenous ) hospitalization last year . Patients require long term oxygen therapy daily basis chronic hypoxemia . Patients respiratory tract infection within 4 week prior Visit 1 . Patients concomitant pulmonary disease Patients history asthma Any patient lung cancer history lung cancer ( within last 5 year ) Patients history certain cardiovascular comorbid condition</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>QVA149</keyword>
	<keyword>indacaterol</keyword>
	<keyword>NVA237</keyword>
	<keyword>COPD</keyword>
	<keyword>fluticasone/salmeterol</keyword>
</DOC>